ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Birmingham, AL, USA:

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non...

Enrolling
Renal Cell Carcinoma (RCC)
Small Cell Lung Cancer
Drug: AL8326 40 mg
Drug: AL8326 60 mg

Phase 2

Advenchen

Birmingham, Alabama, United States and 6 other locations

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

Phase 3

AbbVie
AbbVie

Birmingham, Alabama, United States and 322 other locations

Locations recently updated

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small...

Enrolling
Carcinoma Non Small Cell Lung
Advanced Non Small Cell Lung Cancer
Drug: Sarilumab
Drug: Marlotamig

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Birmingham, Alabama, United States and 16 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS ...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: Pembrolizumab
Drug: BBO-10203

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Birmingham, Alabama, United States and 37 other locations

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non...

Enrolling
Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Cancer Metastatic
Drug: Docetaxel monotherapy
Drug: PF-08046054

Phase 3

Pfizer
Pfizer

Birmingham, Alabama, United States and 432 other locations

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) wit...

Active, not recruiting
Advanced Non-Small Cell Squamous Lung Cancer
Advanced Lung Carcinoma
Drug: silevertinib (BDTX-1535) monotherapy

Phase 1, Phase 2

Black Diamond Therapeutics

Birmingham, Alabama, United States and 28 other locations

Study With Various Immunotherapy Treatments in Participants With Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Zimberelimab

Phase 2

Gilead Sciences
Gilead Sciences

Birmingham, Alabama, United States and 52 other locations

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell...

Enrolling
Non-small Cell Lung Cancer
Drug: Pumitamig
Drug: Docetaxel

Phase 2

BioNTech
BioNTech

Birmingham, Alabama, United States and 29 other locations

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or...

Active, not recruiting
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Biological: Pembrolizumab
Biological: Ramucirumab

Phase 3

SWOG Cancer Research Network
SWOG Cancer Research Network

Birmingham, Alabama, United States and 566 other locations

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)

amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) i...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Amivantamab
Drug: Capmatinib

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Birmingham, Alabama, United States and 78 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems